تجاوز إلى المحتوى الرئيسي

بحث

عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
Venous Thromboembolic Risk Assessment of Post-Partum Females in Saudi Arabia Utilizing Royal College of Obstetrics and Gynecology Risk Assessment Model Sanofi Ongoing N/A 4 DIREG_L_06410 King Abdulaziz University Hospital (Jeddah)
An observational registry improving Control of Hypertension and Achieving Normalization Goal Earlier Sanofi Ongoing N/A 4 DIREG_L_05059 Erfan & Bagedo General Hospital (Jeddah)
The Influence of a rapid relief of gastro esophageal reflux disease (GERD) symptoms on the quality of life and patient satisfaction after initiating treatment with a Proton Pump Inhibitor. Sanofi Ongoing N/A 4 DRIEG_L_05705 University District Hospital (Jeddah)
International Diabetes Management Practices Study (Wave 5) Sanofi Ongoing N/A 4 DIREG_R_05941 King Fahad Hospital (Jeddah)
An observational study to monitor the efficacy and tolerability of levofloxacin 250 mg OD for treatment of simple lower UTI in Saudi Arabia Sanofi Ongoing Levofloxacin 4 LEVOF_L_05172 Erfan & Bagedo General Hospital (Jeddah)
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP). Bayer Completed Riociguat 2 BAY 63-2521 / 13605 King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh)
Tracking Biologics Along the Silk Road Janssen-Cilag International NV Ongoing Infliximab / Golimumab / Ustekinumab 4 C0168ARA40 King Khalid University Hospital (Riyadh)
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma orOcular Hypertension. Allergan Ongoing Bimatoprost SR 3 192024-092 King Khaled Eye Specialist Hospital (Riyadh), King Abdullah Medical City (Makkah)
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International, Multicenter, Double Blind, Randomized Placebo Controlled Phase 3 trial (ICR-02/ASCOLT) King Fahad Medical City Ongoing Aspirin 3 ICR-02/ASCOLT King Fahad Medical City (Riyadh)
Efficacy and Safety Assessment of NIlotinib in Chronic Myeloid Leukemia (CML) Patients with Suboptimal Response on Imatinib Therapy (NISRI) KAIMRC Ongoing NILOTINIB 4 RC12/052/R King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
عرض 371 - 380 من 446